Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 2:12:777502.
doi: 10.3389/fimmu.2021.777502. eCollection 2021.

Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature

Bei-Bei Cui  1 , Yun-Ru Tian  1 , Xin-Yue Ma  2 , Geng Yin  1 , Qibing Xie  1
Affiliations
Review

Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature

Bei-Bei Cui et al. Front Immunol. .

Abstract

Background: Immune-mediated necrotizing myopathy (IMNM) is characterized by markedly elevated creatinine kinase and histologically scattered necrotic muscle fibers and generally associated with autoantibodies against signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coA-reductase (HMGCR). Poor clinical response to conventional therapies and relapses commonly occur in severe cases. Anti-B-cell therapies have been used in refractory/relapsing cases.

Methods: The characteristics of a patient with IMNM associated with anti-SRP antibodies including physical examination, laboratory tests, and disease activity assessment were evaluated. Conventional therapy, belimumab treatment schedule, and follow-up data were recorded. Medical records of IMNM patients treated in our department from September 2014 to June 2021 were reviewed to evaluate the efficacy and safety of anti-B-cell therapy for anti-SRP IMNM. A literature review of patients with anti-SRP IMNM treated with anti-B-cell therapies was performed.

Results: We describe a case of a 47-year-old woman with IMNM associated with anti-SRP antibodies who relapsed twice after conventional therapy but showed good response and tolerance to belimumab at 28 weeks follow-up. In this review, three patients from our department were treated with rituximab. Two of the three patients rapidly improved after treatment. Twenty patients and five retrospective studies were included in the literature review. All patients were administered rituximab as an anti-B-cell drug.

Conclusion: Despite a lack of rigorous clinical trials, considerable experience demonstrated that anti-B-cell therapy might be effective for patients with IMNM associated with anti-SRP antibodies. Belimumab in association with steroids might be an encouraging option for refractory/relapsing cases.

Keywords: BAFF; SRP antibody; belimumab; immune-mediated necrotizing myopathy; refractory IMNM; rituximab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Allenbach Y, Mammen AL, Benveniste O, Stenzel W. Immune-Mediated Necrotizing Myopathies Working Group ENMC International Workshop. 224th ENMC International Workshop: Clinico-Sero-Pathological Classification of Immune-Mediated Necrotizing Myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord (2018) 28(1):87–99. doi: 10.1016/j.nmd.2017.09.016 - DOI - PubMed
    1. Mazeda C, Cunha R, Ferreira PG, Barcelos A, Aguiar R. Myopathy Associated With Anti-Signal Recognition Particle Autoantibodies With Pulmonary Involvement and Response to RTX. Rheumatol Int (2021) 04:1–5. doi: 10.1007/s00296-021-04904-5 - DOI - PubMed
    1. Ying S, Li S, Tang S, Sun Q, Fang D, Li Y, et al. . Immune-Mediated Necrotizing Myopathy Initially Presenting as Erythema Nodosum. J Inflamm Res (2020) 13:471–6. doi: 10.2147/JIR.S270114 - DOI - PMC - PubMed
    1. Mehta P, Dorsey-Campbell R, Dassan P, Nelson-Piercy C, Viegas S. Difficult Case: RTX in Anti-SRP Antibody Myositis in Pregnancy. Pract Neurol (2019) 19(5):1–3. doi: 10.1136/practneurol-2018-002168 - DOI - PubMed
    1. Nóvoa Medina FJ, Gutiérrez Martínez J, González González Y, Romero Díaz B, Machín García S, Rosas Romero A. Rituximab Therapy in Necrotizing Autoimmune Myopathy Associated With Anti-SRP Antibody: A Clinical Case Review. Reumatol Clin (Engl Ed) (2018) 14(6):379–81. doi: 10.1016/j.reuma.2017.02.009 - DOI - PubMed

MeSH terms